Skip to main content Accessibility help

Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia Surveillance

  • Juliette Morgan (a1), Martin I. Meltzer (a1), Brian D. Plikaytis (a1), Andre N. Sofair (a2), Sharon Huie-White (a2), Steven Wilcox (a3), Lee H. Harrison (a4), Eric C. Seaberg (a4), Rana A. Hajjeh (a1) and Steven M. Teutsch (a5)...



To determine the mortality, hospital stay, and total hospital charges and cost of hospitalization attributable to candidemia by comparing patients with candidemia with control-patients who have otherwise similar illnesses. Prior studies lack broad patient and hospital representation or cost-related information that accurately reflects current medical practices.


Our case-control study included case-patients with candidemia and their cost-related data, ascertained from laboratory-based candidemia surveillance conducted among all residents of Connecticut and Baltimore and Baltimore County, Maryland, during 1998 to 2000. Control-patients were matched on age, hospital type, admission year, discharge diagnoses, and duration of hospitalization prior to candidemia onset.


We identified 214 and 529 sets of matched case-patients and control-patients from the two locations, respectively. Mortality attributable to candidemia ranged between 19% and 24%. On multivariable analysis, candidemia was associated with mortality (OR, 5.3 for Connecticut and 8.5 for Baltimore and Baltimore County; P < .05), whereas receiving adequate treatment was protective (OR, 0.5 and 0.4 for the two locations, respectively; P < .05). Candidemia itself did not increase the total hospital charges and cost of hospitalization; when treatment status was accounted for, having received adequate treatment for candidemia significantly increased the total hospital charges and cost of hospitalization ($6,000 to $29,000 and $3,000 to $22,000, respectively) and the length of stay (3 to 13 days).


Our findings underscore the burden of candidemia, particularly regarding the risk of death, length of hospitalization, and cost associated with treatment (Infect Control Hosp Epidemiol 2005;26:540-547).


Corresponding author

Mycotic Diseases Branch, Centers for Disease Control and Prevention, 1600 Clifton Road, Mail-stop C-09, Atlanta, GA


Hide All
1.Beck-Sague, CM, Jarvis, WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:12471251.
2.Fisher-Hoch, SP, Hutwagner, L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995;21:897904.
3.Pittet, D, Wenzel, RP. Nosocomial bloodstream infections: secular trends in rate, mortality, and contribution to total hospital deaths. Arch Intern Med 1995;155:11771184.
4.Trick, WE, Fridkin, SK, Edwards, JR, Hajjeh, RA, Gaynes, RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002; 35:627630.
5.Hajjeh, RA, Sofair, AN, Harrison, LH, et al. Fluconazole resistance among Candida bloodstream isolates: incidence and correlation with outcome from a population-based study. Presented at the 39th Annual Meeting of the Infectious Diseases Society of America; October 2528, 2001; San Francisco, CA.
6.Pfaller, MA, Jones, RN, Messer, SA, Edmond, MB, Wenzel, RP. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;31:327332.
7.Jarvis, WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995;20:15261530.
8.Edmond, MB, Wallace, SE, McClish, DK, Pfaller, MA, Jones, RN, Wenzel, RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 1999;29:239244.
9.Pinner, RW, Teutsch, SM, Simonsen, L, et al.Trends in infectious diseases mortality in the United States. JAMA 1996;275:189193.
10.Pittet, D, Li, N, Woolson, RF, Wenzel, RP. Microbiologic factors influencing the outcome of nosocomial bloodstream infections: a 6-year validated, population-based model. Clin Infect Dis 1997;24:10681078.
11.Pittet, D, Tarara, D, Wenzel, RP. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:15981601.
12.Wey, SB, Motomi, M, Pfaller, MA, Woolson, RF, Wenzel, RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:26422645.
13.Rentz, AM, Halpern, MT, Bowden, R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781788.
14.Guglaudsson, O, Gillespie, S, Lee, K, et al.Attributable mortality of candidemia, revisited. Clin Infect Dis 2003;37:11721177.
15.Chime. ChimeData Program. Wallingford, CT: Chime, Connecticut Hospital Association.
16.Health Services Cost Review Commission. Health Services Cost Review. Baltimore: Department of Health and Mental Hygiene of the State of Maryland.
17.Pappas, PG, Rex, JH, Sobel, JD, et al.Guidelines from the Infectious Diseases Society of America: guidelines for treatment of candidiasis. Clin Infect Dis 2004;38:161189.
18.Haddix, AC, Corso, PS, Gorsky, RD. Costs. In: Haddix, AC, Teutsch, SM, Corso, PS, eds. Prevention Effectiveness, ed. 2. New York: Oxford University Press; 2003:5376.
19.Meitzer, MI. Introduction to health economics for physicians. Lancet 2001;358:993998.
20. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 1999 rates. 63 Federal Register 41099 (1998).
21. Medicare program: changes to the hospital inpatient prospective payment systems and fiscal year 2000 rates. 64 Federal Register 41620 (1999).
22.Bureau of Labor Statistics. Consumer Price Index. Washington, DC: Bureau of Labor Statistics, U.S. Bureau of Labor Statistics.
23.Goff, DASierawski, SJ, Fass, RJ. Cost analysis of Candida infection among surgical intensive care unit patients. Clinical Drug Investigation 1996;12:176180.
24.Wilson, LS, Reyes, CM, Stolpman, M, Speckman, J, Allen, K, Beney, J. The direct cost and incidence of systemic fungal infections. Value Health 2002;5:2634.
25.Torf, K. Economic aspects of treatment for fungal infections in cancer patients. Eur J Clin Microbiol Infect Dis 1997;16:98107.
26.Rosenthal, GE, Harper, DL, Quinn, LM, et al.Severity-adjusted mortality and length of stay in teaching and nonteaching hospitals: results of a regional study. JAMA 1997;278:485490.
27.Young, DS, Sachais, BS, Jefferies, LC. The cost of disease. Clin Chem 2000; 46:955966.
28.Diekema, DJ, Messer, SA, Brueggemann, AB, et al.Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002;40:12981302.
29.Kao, AS, Brandt, ME, Pruitt, WR, et al.The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin Infect Dis 1999;29:11641170.


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed